$34.10

-0.64 (-1.84%)

11/21/2008 4:02 PM

AstraZeneca plc (ADR) (AZN)

CAPS Rating:

The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating AZN

Add Stock to Watchlist

What the Community Thinks

Total Members

349 Outperforms

26 Underperforms

All-Stars

116 Outperforms

6 Underperforms

Wall Street

7 Outperforms

2 Underperforms

Members bullish on AZN are also bullish on:

Members bearish on AZN are also bearish on:

Ticker Tags

Major 2006 Lawsuit (3), Mega Cap (60), Major 2005 Lawsuit (7), Multinational Company (16), Big Pharma (12), United Kingdom (43), Dividend (191), Pharmaceuticals (148)
Suggest a tag

AstraZeneca plc (ADR) At A Glance

Current Price:	$34.10
Last Trade Time:	11/21/2008 4:02 PM
Open:	$34.98
Previous Close:	$34.74
Daily Range:	$32.58 - $35.03
52-Week Range:	$34.61 - $49.85
Volume:	2,805,571
Market Cap:	$50.25B
P/E Ratio:	9.29
Compare Our Special Broker Offers!

Stock Trends

AZN VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for AZN

Pill as good as chemo on lung cancer, but costlier
11/21/2008 9:25:00 AM - AP
AstraZeneca wins first round in Teva litigation
11/20/2008 5:37:00 PM - AP
A look at economic developments around the world
11/20/2008 12:37:00 PM - AP
World stocks tumble on recession fears
11/20/2008 10:57:00 AM - AP

More Headlines...

Top Bull Pitch

Recs

1 AstraZeneca plc (ADR) (AZN)

Avatar catmon (85.83) Submitted: 6/19/08 3:55 PM

Arimidex use will increase sales with favorable ATAC trial released.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1 AstraZeneca plc (ADR) (AZN)

Avatar KingPortu (66.85) Submitted: 10/29/07 2:34 PM

I like the MedImmune acquisition but their balance sheet looks like crap- 5billion in cash vs 15billion in debt, plus negative earnings and revenue. Think it will take some time before the MedImmune acquisition starts to pay off

Replies: 0 | Reply | Permalink

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 54 : 1 2 3 4 5 Next » Jump to page:

Recs 0 (AZN) Frogchick (55.58) Submitted: 11/21/08 10:46 AM : Start Price: $34.11 AZN Score: -0.22 should do well in future. Makes great drugs Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AZN) WilliamCrook2007 (22.91) Submitted: 11/20/08 2:47 PM : Start Price: $35.78 AZN Score: -0.70 ibd Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AZN) TMFBiologyFool (98.10) Submitted: 10/30/08 2:04 PM : Start Price: $41.68 AZN Score: 1.83 A P/E of 8.5? Even with a patent cliff that sounds pretty cheap. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AZN) MViscio1 (26.43) Submitted: 10/23/08 1:55 PM : Start Price: $37.41 AZN Score: 4.89 GOOD HEALTH CARE COMPANY Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AZN) phatinvestor007 (90.65) Submitted: 10/18/08 11:42 AM : Start Price: $39.71 AZN Score: 6.42 Company is very focused. With Medimmune they will become a major player in the multibillion dollar mAb market Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 54 : 1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 9 of 9

picks per page. CHANGE Expand All Pitches Collapse All Pitches

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackCowenandCo	78.45	10/29/08		NS	$38.38	-11.15%	-18.75%	+7.59
	TrackHSBC	92.10	06/26/08		NS	$42.91	-20.53%	-41.92%	-21.39
	TrackJPMorgan	< 20	04/18/08		NS	$41.17	-17.17%	-45.25%	-28.08
	TrackCitigroup	< 20	04/02/08		NS	$40.01	-14.78%	-44.51%	+29.73
	TrackJimCramer	85.65	04/01/08		3W	$40.15	-15.07%	-44.49%	+29.42
	TrackHAndW	< 20	12/31/07		NS	$40.91	-16.65%	-48.13%	+31.49
	TrackBrandes	< 20	09/30/07		NS	$47.84	-28.71%	-50.30%	+21.58
	TrackEdwardOwens	99.48	09/30/07		NS	$47.84	-28.71%	-50.30%	+21.58
	TrackBearStearns	25.14	01/12/07		NS	$52.07	-34.51%	-46.64%	+12.13

Results 1 - 9 of 9

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.